Report #2856250

Received Sep 1, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: FL
Recovered: Unknown
Vaccinated: Aug 4, 2025
Onset: Aug 1, 2025
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	UNK	—

Symptoms (2)

PruritusRash

Symptom narrative

Rash; Itching; This non-serious case was reported by a consumer via call center representative and described the occurrence of rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On 04-AUG-2025, the patient received the 1st dose of Shingrix. In AUG-2025, less than a week after receiving Shingrix, the patient experienced rash (Verbatim: Rash) and pruritus (Verbatim: Itching). The outcome of the rash and pruritus were unknown. It was unknown if the reporter considered the rash and pruritus to be related to Shingrix. It was unknown if the company considered the rash and pruritus to be related to Shingrix. Additional Information: GSK Receipt Date: 08-AUG-2025 Customer reported she received the first dose of Shingrix on 04 Aug 2025. Stated that she developed a rash and itching after receiving the vaccine.